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Renalase, a catecholamine-metabolizing
hormone from the kidney
A novel flavin adenine dinucleotide-dependent amine oxidase that is secreted by the kidney, circulates in the blood, and
modulates cardiac function and systemic blood pressure has recently been discovered. Renalase appears to be a hormone
that metabolizes catecholamines, and its discovery will facilitate our understanding of sympathetic regulation.358 CELL METABOLISM : JUNE 2005
P R E V I E WIt isn’t every day that a new renal hor-
mone is discovered. First, there was re-
acid identity of the two proteins is 70%.
The physiological function of MAO-A
and β adrenoceptor blockade. As a mat-
ter of fact, such an experiment wouldanin. Then came erythropoietin. The real-
sization that the kidney is responsible for
ethe final step in the production of active
avitamin D led to the identification of a
mthird hormone, calcitriol. The kidney also
dproduces various prostaglandins and
vother products that may have substan-
ttial systemic effects.
aRecently published work by Xu et al.
Lemploys a “tour de force” approach to
ngive us a new renal hormone, “renalase”
p(Xu et al., 2005). To find novel renal pro-
cteins, the authors applied a series of se-
ilection criteria to the complete collection
dof clones published by the Mammalian
rGene Collection Project. First, they se-
tlected proteins with less than 20% se-
dquence homology to known proteins.
tThey also focused on proteins contain-
wing signal peptide sequences, which are
Tkey for protein export (of a hormone for
hinstance). They excluded proteins that
(had transmembrane domains; the typi-
hcal secreted protein lacks these. Next,
nNorthern blot analysis was done for each
M
of the 114 candidate genes thus iden-
c
tified. One clone (MGC12474) showed a
M
robust preferential renal expression with
e
lower expression in heart, skeletal mus-
s
cle, and liver. The longest open reading
frame encoded a novel protein of 342 i
amino acids that they termed renalase. n
In human kidney, renalase was present d
in the glomeruli and proximal tubules, d
while in the heart the enzyme was asso- a
ciated with cardiomyocytes. s
The investigators generated a gluta- l
thione synthase-renalase recombinant a
protein in E. coli that they successfully e
purified. They observed that when flavin M
adenine dinucleotide (FAD) was omitted l
during protein synthesis, the synthetic T
renalase had no oxidase activity. Thus, h
renalase is FAD dependent. Renalase o
had a 13.2% amino acid identity with s
monoamine oxidase A (MAO-A), another b
FAD-dependent enzyme. MAO-A and
MAO-B are mitochondrial outer mem- r
brane bound flavoproteins that catalyze n
the oxidative deamination of neurotrans- p
mitters and biogenic amines. A number w
of mechanism-based inhibitors have been c
developed for clinical use as antidepres- T
sants and as neuroprotective drugs. The c
three-dimensional crystal structure of a
MAO-B has been prepared; that for T
MAO-A should follow shortly. The amino bCELL METABOLISM : JUNE 2005hnd MAO-B was elucidated by the
tudy of Norrie disease. The three genes
ncoding NDP, MAO-A, and MAO-B lie w
djacent to one another on the X chro- m
osome. A contiguous chromosomal t
eletion of the three genes causes se- N
ere mental retardation, seizures, hypo- t
onic crises, impaired somatic growth, t
nd altered peripheral autonomic fucion. l
oss of MAO-A and MAO-B is reflected a
eurochemically by severely reduced i
lasma and urinary concentrations of e
atecholamine-deaminated metabolites, t
ncluding dihydroxyphenyl glycol, the l
eaminated metabolite of norepineph- n
ine and epinephrine. An X-linked selec- t
ive MAO-A deficiency has also been n
escribed, whose neurochemical pheno- i
ype closely resembles that in patients s
ith the contiguous gene syndrome. k
he genes encoding MAO-A and MAO-B e
ave also been deleted in the mouse s
Shih, 2004). MAO-A gene-deleted mice
ave increased circulating serotonin, v
orepinephrine, and dopamine, whereas t
AO-B gene-deleted mice show in- i
reased phenylethylamine levels. Both i
AO-detected strains were subjected to l
xogenous stress reaction tests and n
howed an increased response. s
Based on the above information, the t
nvestigators pursued the notion that re- h
alase might be important in amine oxi- t
ation. After identifying an amino-oxi- n
ase domain in the predicted amino t
cid sequence, a host of probable sub- k
trates were lined up for testing. Rena- p
ase gobbled up dopamine, epinephrine, t
nd noreipnephrine in that order of pref- 2
rence. However, neither MAO-A nor t
AO-B inhibitors (pargyline and clorgy- t
ine, respectively) could block renalase. M
he authors then purified renalase from n
uman urine. The material again metab- e
lized catecholamines with the same c
ubstrate specificity. Anti-renalase anti- t
ody blocked the effects. c
The authors then tested renalase in d
ats. Sprague-Dawley rats given intrave- s
ous renalase decreased their blood o
ressures by 25%; the effect dissipated
ithin minutes. Heart rate decreased ac- e
ordingly, as did cardiac contractility. e
he effects were dose dependent. The b
ardiovascular effects described by the v
uthors were dramatic and convincing. t
he animals behaved as if they had s
peen suddenly subjected to a massive αave been a nice positive control.
Given these tantalizing basic findings,
hat is the evidence that a catechola-
ine-catabolizing enzyme produced in
he kidney might be clinically relevant?
orepinephrine-containing renal sympa-
hetic nerves innervate all segments of
he kidney (DiBona, 2003). Neural regu-
ation has a major effect on renal sodium
nd volume reabsorption, which in turn
nfluences blood pressure. The tubular
ffects are independent of vasoconstric-
ion. Neural activity also largely regu-
ates renin release. There are three renal
euroeffectors: the vasculature, the jux-
aglomerular granular cells, and the re-
al tubules. The renal neural regulation
s modulated by renal afferent neural
ignals. However, the notion that the
idney might produce a hormone influ-
ncing catecholamines and their dispo-
ition was not anticipated.
Xu et al. (2005) found that renalase is
irtually absent in dialysis patients, al-
hough normal subjects have the mater-
al in abundance. Dialysis patients have
ncreased sympathetic tone. Their circu-
ating catecholamines are higher than
ondialysis control subjects. Furthermore,
ympathetic activity can be measured at
he nerve level with microneurography in
uman subjects. The technique involves
he placement of a very fine tungsten
eedle into the peroneal nerve, where
he nerve wraps around the fibula at the
nee. Dialysis patients are generally hy-
ertensive and have increased sympa-
hetic nerve traffic (Augustyniak et al.,
002). However, when bilateral nephrec-
omy is performed in dialysis patients,
heir hypertension generally goes away.
oreover, their muscle sympathetic
erve activity is reduced to normal or
ven lower levels. Conceivably, the in-
reased sympathetic tone in dialysis pa-
ients is attributable to renalase defi-
iency. Nevertheless, the presence of
iseased kidneys must also supply a
ignal since bilateral nephrectomy obvi-
usly cannot restore renalase.
The authors show that dopamine is
ffectively degraded by renalase. How-
ver, dopamine is associated with lower
lood pressure and decreased cardio-
ascular risk. Felder et al. (2002) found
hat in human essential hypertension,
ingle-nucleotide polymorphisms of a G
rotein-coupled receptor kinase, GRK4γ,359
P R E V I E Wincreased G protein-coupled receptor H
Vkinase (GRK) activity and caused serine
phosphorylation and uncoupling of the
tdopamine D(1) receptor from its G pro-
itein/effector enzyme complex in the re-
wnal proximal tubule. The effect was veri-
lfied in transfected Chinese hamster
aovary cells. Their findings would suggest
tthat diminished dopaminergic tone would
tincrease blood pressure and cardiovas-
rcular risk. Renalase could have an ad-
tverse effect on blood pressure by low-
tering dopamine, particularly in the kidney.
sThere are distinct differences between
t
MAO-A and renalase. Renalase is se-
p
creted into the circulation while MAO-A b
and MAO-B are confined to the intracel- (
lular mitochondrial membrane. The au- n
thors indicate that amine-oxidase activ- c
ity has been measured in human plasma e
previously. The vascular adhesion pro- o
tein 1 (VAP-1) is believed to mediate that m
activity. The VAP-1 protein is a copper- a
containing semicarbazide-sensitive amine t
oxidase that is secreted by vascular c
smooth muscle cells, adipocytes, and s
rendothelial cells (Stolen et al., 2004).360owever, the substrate specificity of F
AP-1 is very distinct from renalase. M
The discovery of renalase will poten- F
ially contribute to our understanding of
ncreased cardiovascular risk in patients M
ith chronic renal disease. Cardiovascu-
ar risk correlates with sympathetic tone B
nd circulating norepinephrine concen- G
rations. Since renalase is made within
he kidney, possibly its major function
Sesides within the organ. Renal sympa-
hetic nerve activity performs the fine-
Auning of cardiovascular and blood pres- a
ure regulation. A potentially beneficial
Dherapeutic effect for patients with hy-
ertension or heart failure would be the F
Zlockade of α1-adrenergic receptors
SDiBona, 2003). By metabolizing norepi-
Sephrine within the kidney, renalase
Sould perform that function. The discov-
ry of renalase will surely usher in a host S
f additional investigations into the B
echanisms by which renalase may act C
nd the role it plays. Most likely, the ac- X
ions of renalase will be important to L
ardiovascular health in general and G
hould extend far beyond patients with
educed renal function. Driedrich C. Luft
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